Respiratory Syncytial Virus Infection: From Biology to Therapy A Perspective

Respiratory syncytial virus (RSV) is responsible for significant morbidity and mortality, particularly in infants younger than 18 months and in the elderly. To date, there are few effective treatment options available to prevent or treat RSV infections. Attractive therapeutic strategies include targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohapatra, Shyam S, Lockey, Richard F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2008
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650942/
https://www.ncbi.nlm.nih.gov/pubmed/23283306
http://dx.doi.org/10.1097/WOX.0b013e31816549a2
Descripción
Sumario:Respiratory syncytial virus (RSV) is responsible for significant morbidity and mortality, particularly in infants younger than 18 months and in the elderly. To date, there are few effective treatment options available to prevent or treat RSV infections. Attractive therapeutic strategies include targeting host epithelial adhesion molecules required for RSV infection, enhancing localized cell-mediated immunity, interfering with RSV viral gene expression and developing a multigene DNA vaccine. The most recent data supporting the advantages and limitations of each of these approaches are discussed in detail. Several promising strategies offer hope for safe and effective prophylaxis and treatment of RSV infection.

Ejemplares similares